

Mark A Samaan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4338722/publications.pdf>

Version: 2024-02-01

65
papers

1,404
citations

304743

22
h-index

345221

36
g-index

67
all docs

67
docs citations

67
times ranked

2092
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a histological index for UC. <i>Gut</i> , 2017, 66, 50-58.	12.1	264
2	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 222-234.	17.8	82
3	A Systematic Review of the Measurement of Endoscopic Healing in Ulcerative Colitis Clinical Trials. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1465-1471.	1.9	69
4	Reproducibility of histological assessments of disease activity in UC. <i>Gut</i> , 2015, 64, 1765-1773.	12.1	66
5	Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1480-1486.e3.	4.4	55
6	The development of a magnetic resonance imaging index for fistulising Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 516-528.	3.7	53
7	Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 440-449.	1.9	47
8	Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1021-1042.	3.7	41
9	Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. <i>Frontline Gastroenterology</i> , 2017, 8, 196-202.	1.8	41
10	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 607-618.	1.3	39
11	Small bowel video capsule endoscopy: an overview. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 323-329.	3.0	37
12	Incidence and Severity of Prepouch Ileitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 662-668.	1.9	35
13	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 679-697.	8.1	33
14	Laparoscopic Adjustable Gastric Banding for Morbid Obesity in a Patient with Situs Inversus Totalis. <i>Obesity Surgery</i> , 2008, 18, 898-901.	2.1	29
15	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 360-369.e2.	1.0	29
16	Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 937-944.	1.9	29
17	Tofacitinib in Acute Severe Ulcerative Colitis: A Real-World Tertiary Center Experience. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e147-e149.	1.9	28
18	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2020, 69, gutjnl-2020-321927.	12.1	28

#	ARTICLE	IF	CITATIONS
19	Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1432-1452.	3.7	28
20	Recent advances in monoclonal antibody therapy in IBD: practical issues. <i>Frontline Gastroenterology</i> , 2019, 10, 409-416.	1.8	27
21	Biologic therapies for Crohn's disease: optimising the old and maximising the new. <i>F1000Research</i> , 2019, 8, 1210.	1.6	25
22	Current Practices in Ileal Pouch Surveillance for Patients With Ulcerative Colitis: A Multinational, Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 735-743.	1.3	24
23	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 271-281.	8.1	23
24	Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation. <i>Inflammatory Bowel Diseases</i> , 2016, 22, E39-E40.	1.9	22
25	An Update on Anti-TNF Agents in Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 479-494.	2.2	17
26	Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 292-302.	3.7	17
27	Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1271-1279.	3.1	15
28	The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre. <i>GastroHep</i> , 2020, 2, 318-326.	0.6	14
29	Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response. <i>Frontline Gastroenterology</i> , 2020, 11, 188-193.	1.8	14
30	Golimumab in the treatment of ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481882126.	3.2	13
31	Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2021, 70, 1044-1052.	12.1	13
32	Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. <i>Annals of Gastroenterology</i> , 2020, 33, 170-177.	0.6	13
33	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1108-1117.	3.7	13
34	Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres. <i>Frontline Gastroenterology</i> , 2018, 9, 221-231.	1.8	12
35	Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1051-1058.	1.5	12
36	Refeeding syndrome in adults receiving total parenteral nutrition: An audit of practice at a tertiary UK centre. <i>Clinical Nutrition</i> , 2019, 38, 1457-1463.	5.0	11

#	ARTICLE	IF	CITATIONS
37	Ischaemic colitis: practical challenges and evidence-based recommendations for management. <i>Frontline Gastroenterology</i> , 2021, 12, 44-52.	1.8	11
38	Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e125-e126.	1.9	10
39	Vedolizumab-Associated Drug-Induced Liver Injury: A Case Series. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e32-e34.	1.9	10
40	Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study. <i>Frontline Gastroenterology</i> , 2022, 13, 517-523.	1.8	9
41	Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2017, Volume 10, 57-66.	2.3	8
42	An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 678-688.	3.7	7
43	Contemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel Approach. <i>Circulation: Heart Failure</i> , 2021, 14, .	3.9	7
44	A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1511-1522.	1.3	6
45	The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 975-977.	3.1	3
46	Implementation of an intervention bundle leads to quality improvement in ulcerative colitis endoscopy reporting. <i>GastroHep</i> , 2020, 2, 309-317.	0.6	3
47	The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study. <i>JMIR Research Protocols</i> , 2018, 7, e11218.	1.0	3
48	P673 Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S451-S452.	1.3	2
49	P535 The use of therapeutic drug monitoring for infliximab and adalimumab in inflammatory bowel disease: Practice patterns, understanding and interpretation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S376-S377.	1.3	1
50	Letter: immune checkpoint inhibitor-induced colitis "shouldn't we be checking more often?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 472-473.	3.7	1
51	OTH-01...A complex lower gastrointestinal polyp MDT improves evidence-based decision making and efficiency of endoscopy scheduling. , 2019, , .		1
52	Vedolizumab Dose Escalation: In for a Penny, in for a Pound?. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1772-1774.	2.3	1
53	Checking the chart in severe gastritis: a case in point. <i>Frontline Gastroenterology</i> , 2022, 13, f1gastro-2021-101846.	1.8	1
54	5-ASAs in Crohn's Disease: Time to Stop the Salicylate?. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	1

#	ARTICLE	IF	CITATIONS
55	Editorial: protecting hypoxia-inducible factor and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 733-734.	3.7	1
56	Clinical Remission as Defined by the Mayo Score. <i>Inflammatory Bowel Diseases</i> , 2015, 21, E3-E4.	1.9	0
57	Spots of bother. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212721.	0.5	0
58	Su1658 Incidence and Severity of Pre-Pouch Ileitis: a Distinct Disease Entity or a Manifestation of Refractory Pouchitis?. <i>Gastrointestinal Endoscopy</i> , 2015, 81, AB368.	1.0	0
59	A fluke diagnosis. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216169.	0.5	0
60	Editorial: biologic therapy for chronic pouchitis “are we beginning to meet the unmet need?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 857-858.	3.7	0
61	Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab. <i>The Cochrane Library</i> , 2018, , .	2.8	0
62	PTH-008...Endoscopy reporting in ulcerative colitis: identifying areas of suboptimal practice to define an intervention bundle. , 2019, , .		0
63	Seeing red after a prostate procedure. <i>Gut</i> , 2020, 69, 980-1026.	12.1	0
64	Authors’™ Reply to: Type C Mucosa in Pouch Surveillance: Make-do and Mend Rather Than Start From Scratch?. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1181-1181.	1.3	0
65	Striking the balance with intravenous iron: too much or never enough?. <i>Frontline Gastroenterology</i> , 2021, 12, 361-362.	1.8	0